Skip to content
Menu

Arrowhead Pharmaceuticals, Inc. ARWR

Full chart Compare
Set alert

Price alert · ARWR

All alert types
41.37 USD -2.28 (-5.22%)

Regular-session close

41.40 +0.03 +0.07%

After hours · Nov 20, 4:09 PM ET

41.17 Day range 44.80
38.09 52-week range 89.59
YTD
-37.69%
1 year
+8.61%

5D -4.90 (-10.44%)

424446MonTueWedThuFri42.02
Market cap
5.85B
Revenue (ttm)
450.82M
Profit margin
-160.64%
EPS (ttm)
-5.11
Shares out
141.37M
Forward P/E
-11.22
YTD return
-37.69%
1-year return
+8.61%
50-day average
60.07
200-day average
70.54
Volume
3.91M
Avg volume
2.04M
Open
43.42
Previous close
43.65
Day's range
41.17 – 44.80
52-week range
38.09 – 89.59
Beta
1.37
Analysts
Strong Buy
Price target
105.86 (+155.9%)
Earnings date
Feb 4, 2027

Key statistics

Enterprise value
6.39B
Price / sales
12.97
Price / book
116.21
Revenue growth
-85.30%
Free cash flow
-587.00M
Total cash
1.19B
Total debt
1.41B
Return on equity
-258.93%
Short % of float
11.40%

Fundamental scorecard

4 of 25 checks passed on ARWR’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 1 of 5
  • Growth 1 of 5
  • Profitability 1 of 5
  • Financial health 1 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
ARWR Revenue — quarterly 37.79M
ARWR Net income — quarterly -428.00M
ARWR EPS — quarterly -3.01

Earnings

ARWR recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 4, 2027Dec 30, 2026-1.45———
Nov 12, 2026Sep 30, 2026-1.52-3.04-1.52-100.00%
Aug 4, 2026Jun 30, 2026-1.28-1.36-0.08-6.25%
May 7, 2026Mar 31, 2026-1.09-0.93+0.16+14.68%
Feb 5, 2026Dec 31, 20250.600.22-0.38-63.33%
Nov 25, 2025Sep 30, 2025-0.11157-0.18-0.07-61.33%

Upgrades / downgrades

ARWR analyst upgrades and downgrades
DateFirmActionFromTo
Nov 17, 2026CitigroupmainBuyBuy
Nov 13, 2026RBC CapitalreitOutperformOutperform
Nov 13, 2026StifelmainBuyBuy
Oct 15, 2026Chardan CapitalmainBuyBuy
Oct 15, 2026HC Wainwright & Co.reitBuyBuy
Sep 8, 2026Citigroupinit—Buy

About Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; Novartis Pharma AG; Madrigal Pharmaceuticals, Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on ARWR — it syncs with the Stock Master app.

Insider holders

ARWR insider holders
InsiderRelationLatest transactionDateShares held
ANZALONE CHRISTOPHER RICHARDChief Executive OfficerSaleJan 1, 20263,792,740
APEL DANIEL JOSEPHChief Financial OfficerSaleApr 21, 2026162,905
FERRARI MAURODirectorSaleDec 25, 202569,053
GIVEN DOUGLAS BRUCEDirectorSaleDec 16, 2024124,167
HAMILTON JAMES COfficerSaleApr 22, 2026226,958
LU HONGBO BDirectorSaleMay 11, 202652,012

Institution ownership

ARWR institution ownership
Holder% heldSharesValueReported
Blackrock Inc.10.71%15,140,840626.38MSep 29, 2026
Avoro Capital Advisors LLC7.78%11,000,000455.07MSep 29, 2026
FMR, LLC6.62%9,355,747387.05MSep 29, 2026
Vanguard Portfolio Management LLC4.39%6,210,955256.95MSep 29, 2026
State Street Corporation4.33%6,122,271253.28MSep 29, 2026
Vanguard Capital Management LLC4.33%6,118,719253.13MSep 29, 2026

Fund ownership

ARWR fund ownership
Holder% heldSharesValueReported
iShares Trust-iShares Core S&P Mid-Cap ETF3.56%5,031,501208.15MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.00%4,246,637175.68MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.17%3,067,819126.92MJun 29, 2026
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund1.88%2,663,269110.18MSep 29, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF1.27%1,788,39673.99MSep 29, 2026
Invesco Exchange-Traded Fund Trust-Invesco S&P MidCap Momentum ETF1.27%1,799,30374.44MSep 29, 2026